Table 1.
Clinicopathologic characteristics of 255 patients with ALK-rearranged NSCLC, the data for whom were used for conditional approval of crizotinib27,29
| Patient characteristics (n = 255) | |
| Median (range) age (years) | 51 (21–82) |
| Gender (%) | |
| Male | 123 (48) |
| Female | 133 (52) |
| Eastern Cooperative Oncology Group performance status (%) | |
| 0 | 78 (30) |
| 1 | 137 (54) |
| 2–3 | 40 (16) |
| Race (%) | |
| Caucasian | 161 (63) |
| African-American | 8 (3) |
| Asian | 77 (30) |
| Other | 9 (4) |
| Smoking status (%) | |
| Never-smoker | 178 (70) |
| Former smoker | 71 (28) |
| Current smoker | 6 (2) |
| Histology (%) | |
| Adenocarcinoma | 246 (96.5) |
| Squamous cell carcinoma | 2 (1) |
| Large cell carcinoma | 1 (0.5) |
| Adenosquamous carcinoma | 3 (1) |
| Other | 3 (1) |
| Disease stage (%) | |
| Locally advanced | 14 (5.5) |
| Metastatic | 241 (94.5) |
| Number of prior regimens of systemic therapy (%) | |
| 0 | 15 (6) |
| 1 | 47 (18) |
| 2 | 57 (22) |
| 3 | 54 (21) |
| ≥4 | 82 (32) |